Assessing Risk Classification in Medication-Induced Diabetes during Induction Therapy in Pediatric Acute...

Area of Science:

• Pediatric Oncology
• Endocrinology
• Clinical Research

Background:

• Medication-induced diabetes (MID) is a frequent complication during induction therapy for pediatric acute lymphoblastic leukemia (ALL).
• Risk factors for MID are not well-defined, especially when comparing standard-risk (SR) versus high-risk (HR) ALL treatment regimens.
• Limited data exists on the incidence and specific risk factors for MID in pediatric ALL patients undergoing induction therapy.

Purpose of the Study:

• To evaluate the incidence and identify risk factors for MID during induction therapy in pediatric ALL patients.
• To compare the occurrence of MID and other complications between SR and HR ALL treatment groups.
• To analyze a 20-year cohort of pediatric ALL patients from the Maritimes region.

Main Methods:

• Retrospective single-center study conducted at IWK Health, Halifax, Nova Scotia.
• Inclusion of 262 pediatric patients diagnosed with ALL between 2000 and 2019.
• Analysis of patient demographics, treatment regimens (SR vs. HR), and clinical data to identify MID risk factors.

Main Results:

• Older age, higher body mass index, advanced central nervous system status, Trisomy 21, and prednisone use were identified as risk factors for MID.
• Patients treated with high-risk (HR) regimens experienced significantly more complications, including MID and infections, compared to standard-risk (SR) patients.
• The study identified specific demographic and clinical factors associated with increased MID risk in pediatric ALL.

Conclusions:

• Routine screening for medication-induced diabetes is recommended during induction therapy for pediatric ALL.
• High-risk ALL patients are particularly vulnerable to MID and other treatment-related complications.
• Understanding risk factors can guide proactive management and improve outcomes for pediatric ALL patients.